Alphyn completed Phase 2a clinical trial cohort first recruitment

Alphyn Biologics, a clinical-stage dermatology company developing the first multi-target therapeutic, today announced the completion of cohort 1 enrollment for the Phase 2a clinical trial of AB-101a
.
AB-101a is a topical candidate
for the treatment of mild to moderate atopic dermatitis (AD) in adults and children older than 2 years.
The first cohort enrolled AD patients without bacterial infection
, which is sometimes accompanied by bacterial infection.
Top-line results are expected in about eight weeks
.

This randomized, solvent-controlled, double-blind trial evaluated AB-101a regimens at multiple sites using a standard scale for AD
.
Recruitment for the second cohort of the trial is ongoing, and this cohort trial is unique in that it focuses on the treatment of AD patients with concurrent bacterial infections, including Staphylococcus aureus and drug-resistant Staphylococcus aureus infections
.
Alphyn expects AB-101a to be effective against both non-infectious and infectious forms of AD, and expects the drug to provide a comprehensive, safe and convenient treatment option
for patients and physicians.

The AB-101a was developed
using Alphyn's proprietary AB-101 platform.
The platform contains a wide range of bioactive compounds, thus covering multiple mechanisms of action, with the potential to
solve multiple problems related to any target disease.
Due to the strong safety of the AB-101 platform, Alphyn has opened a Phase 2 clinical trial program
.